Which molecular pathways are triggered in cancer cells during treatment of Daraxonrasib (Pan-RAS inhibitor) with ROCK2 Inhibitor?

The papers currently selected in this chat do not provide enough evidence to answer the question regarding molecular pathways triggered specifically by the combination treatment of Daraxonrasib (RMC-6236) and a ROCK2 inhibitor.

While the provided literature characterizes the independent molecular mechanisms of Daraxonrasib and various ROCK2 inhibitors, no studies in the current context evaluate these two agents in a combination regimen.

The available research provides the following independent data:
* Daraxonrasib (RMC-6236) is a RAS-MULTI(ON) tricomplex inhibitor that binds the active, GTP-bound state of KRAS, NRAS, and HRAS (Direct, High; PMID: 41670434) «✓ PMID:41670434». It acts as a "GAP mimetic" to restore GTPase activity in mutant RAS (Direct, High; DOI: 10.1515/hsz-2025-0249) and disrupts the formation of the SHOC2-KRAS-PP1C (SKP) «✓ DOI:10.1515/hsz-2025-0249» complex, thereby inhibiting RAF-MEK-ERK signaling (Direct, High; PMID: 41519889) «✓ PMID:41519889».
* ROCK2 inhibitors (such as KD025 or SR3677) are reported to suppress ZEB1-mediated DNA damage repair in pancreatic cancer (Direct, High; PMID: 31783584) «✓ PMID:31783584» and modulate the ATM/homologous recombination (HR) repair pathway in glioma (Direct, High; PMID: 35145081) «✓ PMID:35145081». They also influence the PI3K/AKT signaling axis and TGF-β-SMAD transcriptional activity (Direct, High; PMID: 34639115, PMID: 41654799) «✓ PMID:34639115» «✓ PMID:41654799».

To find more targeted evidence, please start a new literature search or chat with the following search directions:
1. Synergy between RMC-6236 (daraxonrasib) and Rho-associated kinase (ROCK) inhibitors in mutant KRAS or NRAS cancer models.
2. Molecular crosstalk between pan-RAS(ON) tricomplex inhibitors and the ROCK2-ZEB1-ATM signaling axis in therapy-resistant solid tumors.
3. Effect of combined RAS-MULTI(ON) and ROCK2 inhibition on the actin cytoskeleton and adaptive resistance pathways in pancreatic ductal adenocarcinoma.

Unverified Table Citations

The following table rows had citations that could not be verified:

• PMID: 23136253 — VSIG2 scaffolding LAMTOR2 and mTOR: activates mTOR signaling — Enhances the interaction between LAMTOR2 and mTOR within ...
  Failed: conclusion — The paper PMID:23136253 provided (Index 4) is a primary research paper titled 'Pancreatic cancer' published in 2024, whereas the actual PMID for the referenced VSIG2 study in the provided text appears to be different (the provided paper text is correct but the metadata index/pmid link for VSIG2 results indicates the paper is primary research about VSIG2/PDAC).
  Possible alternatives (unverified): PMID:41519889 (49% topic match); PMID:25323927 (45% topic match)

The synthesis of the provided research landscape reveals a profound evolution in targeting the RAS–MAPK signaling axis, progressing from early characterizations of Rho-associated kinase (ROCK) functions to the current emergence of multiselective tricomplex inhibitors like daraxonrasib (RMC-6236). This narrative integrates mechanistic insights into tumor maintenance, adaptive resistance, and therapeutic synergy across diverse malignancies.

1. Phases of Evidence Evolution

The evidence corpus transitions through three distinct scientific phases characterized by shifting priorities from general signaling mechanics to mutation-specific targeting and comprehensive pathway abrogation.

• Early Phase (Median Year ~2014): This phase established the fundamental constraints of RAS druggability and the redundant roles of downstream effectors. Research defined the binary switch mechanism of RAS (Tier 1, High; PMID: 28666118) and identified the essential role of the farnesyl modification for membrane association (Tier 1, High; PMID: 25323927). Initial attempts at direct inhibition focused on allosteric control of the Switch-II pocket in KRAS G12C (Tier 1, High; PMID: 24256730).
• Stable Phase (Median Year ~2019): Concentration shifted toward characterizing co-dependencies and adaptive resistance. The role of ROCK2 emerged as a critical driver of chemoresistance via ZEB1-mediated DNA repair (Tier 1, High; PMID: 31783584) and as a modulator of TGF-β-SMAD signaling (Tier 1, High; PMID: 41654799). This period also identified SHOC2 as a pivotal scaffold for RAF dimerization in RAS-mutant contexts (Tier 1, High; PMID: 31182717, PMID: 31577942).
• Emerging Phase (Median Year ~2025): The current frontier involves tricomplex inhibitors (TCIs) that target the active "ON" state of RAS. Daraxonrasib (RMC-6236) and its tool compound RMC-7977 represent a paradigm shift, providing multiselective inhibition of GTP-bound KRAS, NRAS, and HRAS (Tier 1, High; PMID: 41670434, PMID: 41186497). This phase investigates the "GAP mimetic" activity of these inhibitors to restore mutant RAS turnover (Tier 1, High; DOI: 10.1515/hsz-2025-0249).

2. Network Structure and Relationships

The research landscape displays high density and an average degree centered on three primary hubs: KRAS, ROCK2, and SHOC2. These hubs orchestrate the transition from simple signaling to complex survival networks.

• Hubs: SHOC2 acts as a central hub, appearing as an essential bottleneck in genome-scale screens of RAS(Q61)-mutant cancers. KRAS serves as the primary node for therapeutic interventions, while ROCK2 is a hub for cross-domain integration between cytoskeleton remodeling and therapy resistance.
• Bridges: ZEB1 acts as a functional bridge, linking ROCK2 activity to gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC) (Tier 1, High; PMID: 31783584) and temozolomide resistance in glioma (Tier 1, High; PMID: 35145081).
• Inter-cluster Edge Share: There is a significant edge share between RAS inhibition and immune regulation clusters. Multiselective RAS(ON) inhibition by RMC-7977 in NRAS-mutant melanoma drives antitumor immunity by increasing MHC Class I/II expression and recruiting activated CD4+ and CD8+ T cells (Tier 1, High; PMID: 41186497).
• Replication Ratio: The dependency of RAS(Q61) mutants on SHOC2 is consistently replicated across independent Ba/F3 isogenic screens and DepMap analyses, indicating high evidence maturity (Tier 1, High; PMID: 40335703).

3. Mechanisms → Therapies → Outcomes

The transition from mechanistic insight to clinical outcome is most evident in the development of RAS(ON) inhibitors.

• Pharmacological Mechanism: TCIs such as daraxonrasib bind to the intracellular chaperone Cyclophilin A to create a neomorphic interface that sterically blocks the binding of RAS to effectors like RAF (Tier 1, High; PMID: 41519889). Additionally, daraxonrasib restores GTPase activity in mutant RAS, enriching the GDP-bound state and sensitizing the protein to Switch-II pocket inhibitors (Tier 1, High; DOI: 10.1515/hsz-2025-0249).
• Synergistic Outcomes: In PDAC, the combination of daraxonrasib with EGFR and STAT3 inhibitors achieved complete and durable tumor regressions in 50% of genetically engineered mouse models within 30–60 days (Tier 1, High; PMID: 41329731; DOI: 10.1515/hsz-2025-0249). In multiple myeloma models, the pan-RAS inhibitor ADT-007 showed highly potent killing with IC50 values ranging from 0.76 to 12 nM (Tier 2, High; DOI: 10.1182/blood-2024-207683).
• Clinical Efficacy: Early phase I/Ib data for daraxonrasib (RMC-6236) show a median progression-free survival (mPFS) of 8.5 months in KRAS G12X-mutant PDAC (Tier 1, High; PMID: 41543339). In melanoma, patients treated with daraxonrasib achieved partial and complete responses after multiple cycles of therapy (Tier 1, High; PMID: 41186497).

4. Biases and Reliability

The landscape exhibits a recency effect, with a surge of studies (2024–2026) focusing on GTP-state specific inhibition, reflecting the rapid clinical translation of TCIs.

• Coherence and Divergence: Evidence regarding ROCK isoforms is highly coherent regarding their non-redundant roles. ROCK1 is primarily cytosolic and restrains TGF-β signaling, while ROCK2 is predominantly nuclear and promotes SMAD3/4 nuclear accumulation (Tier 1, High; PMID: 41654799). However, context-dependent effects are observed in migration; ROCK2 inhibition reduces migration in some models (PMID: 31105794) but increases it in others, such as medulloblastoma (Tier 1, High; PMID: 40165809).
• Translational Readiness: The use of sotorasib as a "pan-RAS G12C" inhibitor (effective in NRAS G12C) highlights immediate clinical applicability (Tier 1, High; PMID: 38236605). The robustness of SHOC2 as a synthetic lethal partner with MEK inhibitors suggests it is a high-confidence target for future drug-degrader strategies (Tier 1, High; PMID: 31577942, PMID: 40335703).

Significance Assessment

This landscape matters because it delineates a move toward "total RAS blockade." By integrating pan-RAS(ON) inhibitors with mediators of adaptive feedback (like SHOC2 and ROCK2), research is converging on strategies that not only induce initial regression but prevent the onset of tumor resistance, a critical requirement for long-term survival in RAS-driven cancers.

Unverified Citations

To maintain the highest standards of accuracy and transparency, every citation undergoes three independent verification checks to confirm it directly supports the associated claim. The references below did not satisfy all verification stages. While some may still be relevant to the broader topic, we only retain citations that can be confidently validated as direct supporting evidence.

• PMID:40335703 — -mutant cancers
  Failed: conclusion — The claim '-mutant cancers' is a fragment that does not assert a specific finding, although the paper title mentions RAS-mutant cancers generally.